ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 288

The Rheumatoid Arthritis Susceptibility Gene C5orf30 Is an Immunomodulator in Macrophages

Emma Dorris1, Karen Creevey1, John Moylett1, Simon Tazzyman2, Munitta Muthana2 and Anthony G. Wilson1, 1UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland, 2University of Sheffield Medical School, Sheffield, United Kingdom

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: genetics, immunology and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Innate Immunity and Rheumatic Disease Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: rs26232 in the first intron of C5orf30 has been associated with risk of developing rheumatoid arthritis (RA) and severity of tissue damage. C5orf30 is highly expressed by RA synovial fibroblasts (RASF) and macrophages. Inhibition of C5orf30 in RASF results in increased cellular invasiveness and migration in vitro and inhibition in the collagen-induced arthritis model accentuated joint inflammation and damage. There is no published data on the biological activities of C5orf30 in macrophages.

Methods: Monocyte cell line (THP1) and primary monocyte-derived macrophages (MDM) were used. C5orf30 mRNA was assessed by qPCR and protein via Western blot. Transcript and protein half-lives were assessed using actinomycin D and cyclohexamide. Polarization to M1 and M2a phenotypes and stimulation with TNF and LPS on C5orf30 expression were compared. C5orf30 levels were manipulated using siRNA and functional effects on macrophage biology was assessed using ELISAs, invasion assays, pathogen phagocytosis assays, reactive oxygen species assays, gene expression and intracellular signalling assays. In vivo, antisense morpholino oligonucleotides were used to knockdown C5orf30 in zebrafish. Confocal imaging was used to assess the number of invading macrophages.

Results: C5orf30 has a half-life of 3.13 hours, which does not significantly change with the addition of inflammatory (LPS +IFNγ) or anti-inflammatory (IL-4) stimuli. Protein half-life is 19.54 hours, rising to 22.05 hours when pretreated with LPS+ IFNγ (M1-like) and decreasing to 15.07 hours when pretreated with IL-4 (M2a-like). Polarization to M2a increased C5orf30 protein expression whereas polarization to M1 resulted in phosphorylation of C5orf30 protein and decreased expression of C5orf30 (p=0.01). Treatment with TNF or LPS reduced C5orf30 expression (TNF p=0.001, LPS p=0.02). LPS phosphorylates C5orf30. Pretreatment of cells with the JNK inhibitor SP600125 retarded the phosphorylation of C5orf30 in response to LPS in a dose-dependent manner and prevented downregulation of C5orf30 gene expression. Knockdown of C5orf30 reduced the invasive capacity of macrophages (p=0.003) with an associated decrease in MMP1 (p=0.01), MMP3 (p=0.01) and MMP9 (p=0.03). Decrease in invasion was intensified upon incubation with either TNF (p=0.02) or LPS (p=0.01). C5orf30 knockdown increased phagocytosis when co-stimulated with LPS (p=0.01). C5orf30 knockdown also increased activation of the JNK pathway. In vivo, tail amputations in zebrafish with C5orf30 deficient embryos showed an increased macrophage infiltration at the wound site (p=0.01).

Conclusion: Stimulation with inflammatory mediators induces phosphorylation of C5orf30 and downregulates C5orf30 gene expression, whereas treatment with anti-inflammatory signals increases C5orf30 protein expression. C5orf30 knockdown enhanced the proinflammatory macrophage phenotypes of phagocytosis and JNK activation whilst diminishing the tissue-clearing (M2-like) phenotype of macrophage invasion. This data indicates an important role for C5orf30 in the immunomodulatory regulation of macrophages and is consistent with our previous findings in RASF.


Disclosure: E. Dorris, None; K. Creevey, None; J. Moylett, None; S. Tazzyman, None; M. Muthana, None; A. G. Wilson, None.

To cite this abstract in AMA style:

Dorris E, Creevey K, Moylett J, Tazzyman S, Muthana M, Wilson AG. The Rheumatoid Arthritis Susceptibility Gene C5orf30 Is an Immunomodulator in Macrophages [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/the-rheumatoid-arthritis-susceptibility-gene-c5orf30-is-an-immunomodulator-in-macrophages/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-rheumatoid-arthritis-susceptibility-gene-c5orf30-is-an-immunomodulator-in-macrophages/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology